Home > News > Content

Cardiac Marker Testing Market: Evolving Latest Trends To Lead Global Industry By 2022

Sep 18, 2017

When the heart is injured or stressed, it releases certain substances into the blood, which function as cardiac markers. The cardiac markers are usually enzymes, proteins, and hormones. Thus, quantification of these biomarkers can aid in diagnosing numerous heart disorders, including cardiac ischemia, acute coronary syndrome, and conditions linked to hindered blood supply to the heart. Physicians usually carry out multiple cardiac marker tests for hours to observe the blood level increase and to recognize the seriousness of a heart attack.

Global Cardiac Marker Testing Market: Growth Factors

The major factors boosting the growth of global cardiac marker testing include rising expenditure by different institutes to encourage clinical and research studies in biomarker testing, increasing incidence of cardiovascular disorders, and increasing elderly population. However, issues related to storage and collection of samples, compensation, and strict regulatory recommendation are few factors that can hamper the growth of the global market. In addition, estimation of cardiac marker levels in the labs requires considerable time; thus, it cannot be used in the determination of myocardial infarction during the acute phase further restraining its use.

Global Cardiac Marker Testing Market: Segmentation

The global market for cardiac marker testing can be segmented based on disease, type of testing, product, type, and region. The disease segment of the market is divided into congestive heart failure and myocardial infarction. The type of testing segment of the market is diversified into point-of-care testing and laboratory testing. The product segment of the cardiac marker testing marketis classified into immunofluorescence,immunochromatography, instruments, reagents and kits, chemiluminescence, and enzyme-linked immunosorbent assay. The type segment of the market is divided into C-reactive protein, troponin I and T, brain natriuretic peptide or NT-proBNP, CK-MB, other biomarkers, and myoglobin. The other biomarkers segment of the market is classified into H-FABP, homocysteine, myeloperoxidase, galectin-3, and ischemia-modified albumin. Regionally, the cardiac marker testing market is diversified into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.


E-mail:office@lyher.com

http://www.lyherbio.com